JPWO2023099591A5 - - Google Patents
Info
- Publication number
- JPWO2023099591A5 JPWO2023099591A5 JP2024532454A JP2024532454A JPWO2023099591A5 JP WO2023099591 A5 JPWO2023099591 A5 JP WO2023099591A5 JP 2024532454 A JP2024532454 A JP 2024532454A JP 2024532454 A JP2024532454 A JP 2024532454A JP WO2023099591 A5 JPWO2023099591 A5 JP WO2023099591A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- guide rna
- rna molecule
- gene editing
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306681.4 | 2021-12-01 | ||
| EP21306681 | 2021-12-01 | ||
| PCT/EP2022/083904 WO2023099591A1 (en) | 2021-12-01 | 2022-11-30 | Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024543966A JP2024543966A (ja) | 2024-11-26 |
| JPWO2023099591A5 true JPWO2023099591A5 (https=) | 2025-11-17 |
| JP2024543966A5 JP2024543966A5 (https=) | 2025-11-17 |
Family
ID=79185911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532454A Pending JP2024543966A (ja) | 2021-12-01 | 2022-11-30 | 赤血球特異的ＢＣＬ１１Ａエンハンサーの＋５５ｋｂ領域を編集することにより胎児ヘモグロビン含量を増加させるための方法。 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4441089A1 (https=) |
| JP (1) | JP2024543966A (https=) |
| WO (1) | WO2023099591A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008141248A2 (en) | 2007-05-10 | 2008-11-20 | Agilent Technologies, Inc. | Thiocarbon-protecting groups for rna synthesis |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| AU2014227653B2 (en) | 2013-03-15 | 2017-04-20 | The General Hospital Corporation | Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| KR20210139265A (ko) | 2019-02-13 | 2021-11-22 | 빔 테라퓨틱스, 인크. | 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법 |
| CN114667149A (zh) | 2019-09-09 | 2022-06-24 | 比姆医疗股份有限公司 | 新型核碱基编辑器及其使用方法 |
| WO2021067233A1 (en) * | 2019-09-30 | 2021-04-08 | The Children's Medical Center Corporation | Bcl11a guide and base editor delivery |
-
2022
- 2022-11-30 WO PCT/EP2022/083904 patent/WO2023099591A1/en not_active Ceased
- 2022-11-30 JP JP2024532454A patent/JP2024543966A/ja active Pending
- 2022-11-30 EP EP22826075.8A patent/EP4441089A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Expanding the CRISPR toolbox in zebrafish for studying development and disease | |
| Nishiga et al. | The use of new CRISPR tools in cardiovascular research and medicine | |
| JP2025026840A5 (https=) | ||
| Zhou et al. | Programmable base editing of the sheep genome revealed no genome-wide off-target mutations | |
| Bernardi | The human genome: organization and evolutionary history | |
| Pellagatti et al. | Application of CRISPR/Cas9 genome editing to the study and treatment of disease | |
| JP2020510439A5 (https=) | ||
| JP2021523737A5 (https=) | ||
| Ye et al. | Therapy induced genome chaos: A novel mechanism of rapid cancer drug resistance | |
| JPWO2019217944A5 (https=) | ||
| Gott | Expanding genome capacity via RNA editing | |
| Chen et al. | A mitochondrial disease model is generated and corrected using engineered base editors in rat zygotes | |
| JPWO2021228944A5 (https=) | ||
| JPWO2023099591A5 (https=) | ||
| Naert et al. | Methods for CRISPR/Cas9 Xenopus tropicalis tissue-specific multiplex genome engineering | |
| Randazzo et al. | gEL DNA: A cloning-and polymerase chain reaction–free method for CRISPR-based multiplexed genome editing | |
| Tan et al. | Size-and stereochemistry-dependent transcriptional bypass of DNA alkyl phosphotriester adducts in mammalian cells | |
| Wang et al. | DNA barcode to trace the development and differentiation of cord blood stem cells | |
| Jiao et al. | Random-PE: an efficient integration of random sequences into mammalian genome by prime editing | |
| EP3666898A1 (en) | Gene knockout method | |
| Liu et al. | Highly precise base editing with CC context-specificity using engineered human APOBEC3G-nCas9 fusions | |
| JPWO2022081890A5 (https=) | ||
| Liao et al. | Sequential Amino Acid Mutagenesis-Driven De Novo Evolution of Adenine Deaminases Enables Efficient In Vivo Base Editing in Primate | |
| CN114875033A (zh) | sgRNA、CRISPR/Cas试剂及其应用 | |
| Koslowsky | A historical perspective on RNA editing: how the peculiar and bizarre became mainstream |